Therapy

• Researchers at UCL and UCLH conducted a trial where patients with stage 2 or 3 colorectal cancer received just nine weeks of pembrolizumab immunotherapy before surgery, challenging the standard approach of surgery followed by months of chemotherapy. • Early results showed 59% of patients had no detectable cancer after completing immunotherapy and undergoing surgery, and after 33 months of follow-up, none of the patients have experienced a relapse. • This outcome represents a significant shift in colorectal cancer treatment protocols, suggesting that short bursts of targeted immunotherapy prior to surgery may deliver more durable results than conventional post-operative chemotherapy regimens.

Injectable pembrolizumab can treat several types of cancer and can be administered in under two minutesThousands of patients across England each year will benefit from a new immunotherapy treatment that can be used for several types of cancer, the NHS has announced.The injectable form of pembrolizumab, which can be administered in under two minutes, kills cancer cells by blocking a protein called PD-1, which acts as a brake on immune responses, allowing the immune system to recognise and attack cancer cells. Continue reading...

• The FDA granted accelerated approval to a CRISPR-based gene therapy for severe sickle cell disease on April 20, marking the first approved genetic treatment editing patient blood cells to produce functional hemoglobin. • Clinical trials demonstrated 95% of treated patients experienced elimination or near-elimination of vaso-occlusive crises within 12 months, with durable responses observed for over two years post-treatment. • The therapy addresses a disease affecting approximately 100,000 Americans, primarily of African descent, offering potential cure for patients previously reliant on pain management and blood transfusions.

• Elijah Dottery, diagnosed with sickle cell anemia as a baby, became the first U-M patient to receive the newly FDA-approved stem cell therapy. • The treatment uses patient's own stem cells edited via CRISPR to produce functional hemoglobin, administered at Michigan Medicine. • This breakthrough matters for over 100,000 U.S. sickle cell patients, offering potential cure where prior therapies only managed symptoms.

• Texas A&M researchers developed a nasal spray therapy that reverses brain aging by healing inflammation and restoring memory function. • The treatment targets age-related cognitive decline, turning 'brain fog to brain focus' in preclinical models. • Announced on April 14, 2026, it reshapes future therapies for neurodegenerative diseases.

• FDA has approved an investigational new drug application for synthetic CAR-T (sCAR-T) therapy targeting autoimmune conditions. • The clearance enables clinical trials to test this engineered cell therapy in US patients with refractory autoimmune diseases. • sCAR-T represents a novel approach adapting cancer immunotherapy for immune disorders, potentially offering durable remissions.

Treatment reset wayward immune system of patient with life-threatening conditions, say scientists, in a world firstA woman who lived with three life-threatening autoimmune diseases for more than a decade has returned to a near-normal life after a cell therapy reset her wayward immune system.The 47-year-old had had nine different treatments, none of which had a lasting impact, before receiving the therapy last year at University Hospital Erlangen in Germany. At the time, she required daily blood transfusions and permanent blood thinning medication to control her illness. Continue reading...